ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.504C>A (p.Asp168Glu) (rs777321035)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
LDLR-LOVD, British Heart Foundation RCV000238338 SCV000294750 likely pathogenic Familial hypercholesterolemia 1 2016-03-25 criteria provided, single submitter literature only
Robarts Research Institute,Western University RCV000238338 SCV000484741 likely pathogenic Familial hypercholesterolemia 1 criteria provided, single submitter clinical testing
Invitae RCV001238374 SCV001411180 likely pathogenic Familial hypercholesterolemia 2019-08-20 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid with glutamic acid at codon 168 of the LDLR protein (p.Asp168Glu). The aspartic acid residue is highly conserved and there is a small physicochemical difference between aspartic acid and glutamic acid. This variant is present in population databases (rs777321035, ExAC 0.009%). This variant has been observed in several individuals affected with familial hypercholesterolemia (PMID: 15823276, 27765764, Invitae). ClinVar contains an entry for this variant (Variation ID: 251261). This variant is also described as Asp147Glu (D147E) in the literature. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant disrupts the p.Asp168 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8462973, 28104544, 20828696, 16250003). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Broad Institute Rare Disease Group,Broad Institute RCV000238338 SCV001423093 uncertain significance Familial hypercholesterolemia 1 2020-01-22 no assertion criteria provided curation The p.Asp168Glu variant in LDLR has been reported in one Turkish individual in the homozygous state and in one individual in the heterozygous state with Familial Hypercholesterolemia (PMID: 15823276, 27765764), and has been identified in 0.005782% (2/34592) of Latino chromosomes by the Genome Aggregation Database (gnomAD,; dbSNP rs777321035). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population. This variant has also been reported likely pathogenic in ClinVar (Variation ID: 251261). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. Two additional likely pathogenic variants, resulting in a different amino acid change at the same position, p.Asp168Asn and p.Asp168His, have been reported in association with disease in the literature, supporting that a change at this position may not be tolerated (PMID: 8462973, 28966723, 8882879, 28104544, 16250003, 20828696, 27784735, 25647241, 25545329, 16389549, 28379029, 16205024, 19007590, 15556094, 9259195, 22859806, 9678702 /Variation ID: 183136, 251258). The phenotype of a 5 year old Turkish individual homozygous for this variant is highly specific for Familial Hypercholesterolemia based on tendon xanthoma, arcus cornia, and cholesterol levels consistent with disease (PMID: 15823276). Homozygotes with pathogenic variants in this gene are known to have a more severe and earlier onset phenotype than heterozygotes. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PM5, PP4, PS4_Supporting, PP3 (Richards 2015).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.